Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE)

Q: What does CUSIP 78667J108 represent in this 13F holders report?

CUSIP 78667J108 is the security identifier for SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") used to aggregate holder disclosures.

Q: How many institutions held SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") in Q4 2017?

220 institutional investors reported SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") for Q4 2017. Use the holders table for investor-level position and value details.

CUSIP: 78667J108

Q4 2017 13F Holders as of 31 Dec 2017

Type / Class: Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
Shares outstanding: 62,650,155
Total 13F shares: 44,056,451
Share change: +3,711,422
Total reported value: $7,257,119,465
Put/Call ratio: 80%
Price per share: $164.71
Number of holders: 220
Value change: +$681,492,435
Number of buys: 139
Number of sells: 89

Quarterly Holders Quick Answers

What is CUSIP 78667J108?
CUSIP 78667J108 identifies SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2018
Previous quarter: Q3 2017

Recent filing periods for CUSIP 78667J108:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
FMR LLC	13F	Company	9%	5,616,162	$349,886,000	—	30 Sep 2017	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	7.4%	4,667,359	$290,776,000	—	30 Sep 2017	13F
BlackRock Finance, Inc.	13F	Company	4.7%	2,958,036	$184,286,000	—	30 Sep 2017	13F
VANGUARD GROUP INC	13F	Company	4.5%	2,830,252	$176,325,000	—	30 Sep 2017	13F
Bank of New York Mellon Corp	13F	Company	4.3%	2,710,027	$168,834,000	—	30 Sep 2017	13F
OppenheimerFunds, Inc.	13F	Company	2.9%	1,794,004	$111,766,000	—	30 Sep 2017	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	2.7%	1,699,209	$105,860,000	—	30 Sep 2017	13F
STATE STREET CORP	13F	Company	2%	1,242,765	$77,427,000	—	30 Sep 2017	13F
BB BIOTECH AG	13F	Company	1.7%	1,092,439	$68,059,000	—	30 Sep 2017	13F
JENNISON ASSOCIATES LLC	13F	Company	1.4%	873,750	$54,435,000	—	30 Sep 2017	13F
JPMORGAN CHASE & CO	13F	Company	1.3%	838,094	$52,700,000	—	30 Sep 2017	13F
Palo Alto Investors LP	13F	Company	1.3%	787,251	$49,046,000	—	30 Sep 2017	13F
FEDERATED HERMES, INC.	13F	Company	1.2%	752,557	$46,884,000	—	30 Sep 2017	13F
OAK RIDGE INVESTMENTS LLC	13F	Company	1.2%	736,709	$45,897,000	—	30 Sep 2017	13F
EAGLE ASSET MANAGEMENT INC	13F	Company	1%	627,031	$39,697,000	—	30 Sep 2017	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	0.96%	604,219	$37,643,000	—	30 Sep 2017	13F
FRANKLIN RESOURCES INC	13F	Company	0.76%	474,336	$29,551,000	—	30 Sep 2017	13F
NORTHERN TRUST CORP	13F	Company	0.66%	412,174	$25,678,000	—	30 Sep 2017	13F
BAKER BROS. ADVISORS LP	13F	Company	0.65%	405,485	$25,262,000	—	30 Sep 2017	13F
PICTET ASSET MANAGEMENT LTD	13F	Company	0.61%	379,045	$23,615,000	—	30 Sep 2017	13F
DEUTSCHE BANK AG\	13F	Company	0.6%	378,619	$23,584,000	—	30 Sep 2017	13F
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	0.57%	359,802	$22,416,000	—	30 Sep 2017	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.54%	338,078	$21,062,000	—	30 Sep 2017	13F
VICTORY CAPITAL MANAGEMENT INC	13F	Company	0.53%	331,405	$20,647,000	—	30 Sep 2017	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.49%	308,106	$19,195,000	—	30 Sep 2017	13F
LORD, ABBETT & CO. LLC	13F	Company	0.44%	275,665	$17,174,000	—	30 Sep 2017	13F
FARALLON CAPITAL MANAGEMENT LLC	13F	Company	0.39%	243,500	$15,170,000	—	30 Sep 2017	13F
Casdin Capital, LLC	13F	Company	0.38%	240,000	$14,952,000	—	30 Sep 2017	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.37%	234,026	$14,579,820	—	30 Sep 2017	13F
NORGES BANK	13F	Company	0.37%	229,821	$14,318,000	—	30 Sep 2017	13F
AMUNDI ASSET MANAGEMENT US, INC.	13F	Company	0.29%	181,128	$11,284,000	—	30 Sep 2017	13F
Point72 Asset Management, L.P.	13F	Company	0.28%	178,350	$11,111,000	—	30 Sep 2017	13F
EVENTIDE ASSET MANAGEMENT, LLC	13F	Company	0.25%	159,000	$9,906,000	—	30 Sep 2017	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.24%	151,026	$9,409,000	—	30 Sep 2017	13F
Artal Group S.A.	13F	Company	0.24%	150,000	$9,345,000	—	30 Sep 2017	13F
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.24%	149,564	$9,318,000	—	30 Sep 2017	13F
Clarius Group, LLC	13F	Company	0.21%	129,068	$8,041,000	—	30 Sep 2017	13F
TEACHERS ADVISORS, LLC	13F	Company	0.2%	128,413	$8,000,000	—	30 Sep 2017	13F
TIAA CREF INVESTMENT MANAGEMENT LLC	13F	Company	0.19%	120,514	$7,508,000	—	30 Sep 2017	13F
Alyeska Investment Group, L.P.	13F	Company	0.18%	110,797	$6,903,000	—	30 Sep 2017	13F
GREAT POINT PARTNERS LLC	13F	Company	0.17%	109,500	$6,822,000	—	30 Sep 2017	13F
Invesco Ltd.	13F	Company	0.17%	108,993	$6,790,000	—	30 Sep 2017	13F
CITADEL ADVISORS LLC	13F	Company	0.17%	108,200	$6,741,000	—	30 Sep 2017	13F
CADIAN CAPITAL MANAGEMENT, LP	13F	Company	0.17%	107,561	$6,701,000	—	30 Sep 2017	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.17%	104,016	$6,480,000	—	30 Sep 2017	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.16%	100,312	$6,248,000	—	30 Sep 2017	13F
BAMCO INC /NY/	13F	Company	0.15%	93,458	$5,822,000	—	30 Sep 2017	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.14%	90,596	$5,644,000	—	30 Sep 2017	13F
PICTON MAHONEY ASSET MANAGEMENT	13F	Company	0.14%	86,100	$5,364,000	—	30 Sep 2017	13F
Deutsche Girozentrale DekaBank	13F	Individual	0.1%	63,450	$5,349,000	—	30 Sep 2017	13F

Institutional Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q4 2017

As of 31 Dec 2017, Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) was held by 220 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 44,056,451 shares. The largest 10 holders included PRICE T ROWE ASSOCIATES INC /MD/, FMR LLC, BlackRock Inc., Vanguard Group Inc, WELLINGTON MANAGEMENT GROUP LLP, Bank of New York Mellon Corp, OppenheimerFunds, Inc., STATE STREET CORP, BB BIOTECH AG, and Palo Alto Investors, LLC. This page lists 220 institutional shareholders reporting positions in this security for the Q4 2017 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2017 vs Q3 2017 Across Filers

Q3 2017 holders

168

Q4 2017 holders

220

Holder diff

Investor	Q3 2017 Shares	Q4 2017 Shares	Share Diff	Share Chg %	Q3 2017 Value $	Q4 2017 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.